Enoyl-acyl carrier protein reductase

Enoyl-acyl carrier protein reductase (or ENR) (EC 1.3.1.9), is a key enzyme of the type II fatty acid synthesis (FAS) system. (PMID 15139852) ENR is an attractive target for narrow-spectrum antibacterial drug discovery because of its essential role in metabolism and its sequence conservation across many bacterial species. In addition, the bacterial ENR sequence and structural organization are distinctly different from those of mammalian fatty acid biosynthesis enzymes. (PMID 15105103)

At lower concentrations, Triclosan and Triclocarban provide a bacteriostatic effect by binding to ENR. Atromentin and leucomelone possess antibacterial activity, inhibiting the enzyme in the bacteria Streptococcus pneumoniae.[1]

References

  1. ^ Zheng CJ, Sohn MJ, Kim WG. (2006). "Atromentin and leucomelone, the first inhibitors specific to enoyl-ACP reductase (FabK) of Streptococcus pneumoniae". Journal of Antibiotics 59 (12): 808–12. doi:10.1038/ja.2006.108. PMID 17323650. 

See also

External links

1.3.1: NAD/NADP acceptor
Enoyl-acyl carrier protein reductase/Enoyl ACP reductase · 7-Dehydrocholesterol reductase · Biliverdin reductase · 2,4 Dienoyl-CoA reductase
1.3.3: Oxygen acceptor
1.3.5: Quinone
1.3.99: Other acceptors
B enzm: 1.1/2/3/4/5/6/7/8/10/11/13/14/15-18, 2.1/2/3/4/5/6/7/8, 2.7.10, 2.7.11-12, 3.1/2/3/4/5/6/7, 3.1.3.48, 3.4.21/22/23/24, 4.1/2/3/4/5/6, 5.1/2/3/4/99, 6.1-3/4/5-6
Synthesis
Malonyl-CoA synthesis
Fatty acid desaturases
Triacyl glycerol
Degradation
General
Other

M: MET

mt, k, c/g/r/p/y/i, f/h/s/l/o/e, a/u, n, m

k, cgrp/y/i, f/h/s/l/o/e, au, n, m, epon

m(A16/C10),i(k, c/g/r/p/y/i, f/h/s/o/e, a/u, n, m)